Total Payments
$150,040
2024 Payments
$20,829
Companies
11
Transactions
122
Medicare Patients
3,777
Medicare Billing
$187,692
Payment Breakdown by Category
Consulting$74,713 (49.8%)
Travel$38,385 (25.6%)
Other$33,065 (22.0%)
Food & Beverage$3,642 (2.4%)
Research$235.78 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $74,713 | 23 | 49.8% |
| Travel and Lodging | $38,385 | 45 | 25.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,621 | 7 | 12.4% |
| Honoraria | $14,444 | 2 | 9.6% |
| Food and Beverage | $3,642 | 41 | 2.4% |
| Unspecified | $235.78 | 4 | 0.2% |
Payments by Type
General
$149,804
118 transactions
Research
$235.78
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ROCHE DIAGNOSTICS INTERNATIONAL LTD | $74,213 | 39 | $0 (2024) |
| Merck Sharp & Dohme LLC | $23,196 | 28 | $0 (2023) |
| Aralez Pharmaceuticals US Inc. | $19,792 | 15 | $0 (2017) |
| AstraZeneca UK Limited | $9,269 | 8 | $0 (2019) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $8,831 | 16 | $0 (2023) |
| Abbott Laboratories | $8,569 | 7 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $3,416 | 3 | $0 (2024) |
| PFIZER INC. | $2,500 | 1 | $0 (2017) |
| ABIOMED | $220.60 | 3 | $0 (2024) |
| Janssen Research & Development, LLC | $18.18 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,829 | 14 | ROCHE DIAGNOSTICS INTERNATIONAL LTD ($17,313) |
| 2023 | $11,935 | 12 | Merck Sharp & Dohme LLC ($6,749) |
| 2022 | $36,647 | 21 | ROCHE DIAGNOSTICS INTERNATIONAL LTD ($17,697) |
| 2021 | $3,500 | 1 | ROCHE DIAGNOSTICS INTERNATIONAL LTD ($3,500) |
| 2020 | $12,937 | 15 | Merck Sharp & Dohme Corporation ($6,466) |
| 2019 | $23,212 | 17 | Roche Diagnostics International Ltd ($21,920) |
| 2018 | $3,986 | 8 | Roche Diagnostics International Ltd ($3,453) |
| 2017 | $36,995 | 34 | Aralez Pharmaceuticals US Inc. ($19,792) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/11/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Consulting Fee | Cash or cash equivalent | $2,019.50 | General |
| 11/04/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Consulting Fee | Cash or cash equivalent | $2,885.00 | General |
| 11/04/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Travel and Lodging | In-kind items and services | $183.88 | General |
| 11/04/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Food and Beverage | In-kind items and services | $7.69 | General |
| 10/02/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Travel and Lodging | In-kind items and services | $976.18 | General |
| 10/02/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Food and Beverage | In-kind items and services | $404.19 | General |
| 10/01/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Food and Beverage | In-kind items and services | $17.32 | General |
| 09/01/2024 | Novartis Pharma AG | LEQVIO (Drug) | — | Cash or cash equivalent | $15.18 | Research |
| Study: CKJX839B12301 & CKJX839B12302 • Category: CARDIOVASCULAR | ||||||
| 05/10/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,708.00 | General |
| 05/10/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $854.00 | General |
| 04/07/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Travel and Lodging | In-kind items and services | $10,819.60 | General |
| 03/01/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $854.00 | General |
| 01/18/2024 | ABIOMED | Impella (Device) | — | In-kind items and services | $48.71 | Research |
| Study: Impella • Category: Cardiology/Vascular Diseases | ||||||
| 01/18/2024 | ABIOMED | Impella (Device) | — | In-kind items and services | $35.39 | Research |
| Study: Impella • Category: Cardiology/Vascular Diseases | ||||||
| 09/06/2023 | Abbott Laboratories | OPTIS (Device) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Vascular | ||||||
| 05/15/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,450.00 | General |
| 05/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 05/05/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $175.14 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/05/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/05/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/05/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $34.97 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/04/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $308.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/04/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $307.96 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/04/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $222.31 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/20/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Impella | ABIOMED | $220.60 | 3 |
| CKJX839B12301 & CKJX839B12302 | Novartis Pharma AG | $15.18 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,066 | 1,356 | $238,660 | $47,701 |
| 2022 | 6 | 953 | 1,253 | $246,012 | $51,814 |
| 2021 | 5 | 878 | 1,149 | $204,384 | $43,479 |
| 2020 | 8 | 880 | 1,154 | $205,480 | $44,699 |
Total Patients
3,777
Total Services
4,912
Medicare Billing
$187,692
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 54 | 145 | $127,777 | $25,945 | 20.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 815 | 990 | $33,660 | $6,623 | 19.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 29 | 30 | $17,970 | $3,433 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 36 | 37 | $14,951 | $2,699 | 18.1% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 13 | 24 | $10,615 | $2,157 | 20.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 19 | $8,228 | $1,914 | 23.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $8,855 | $1,615 | 18.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 29 | 31 | $8,506 | $1,566 | 18.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 22 | $6,500 | $1,474 | 22.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 47 | 47 | $1,598 | $274.40 | 17.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 46 | 190 | $164,156 | $35,199 | 21.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 749 | 883 | $30,688 | $6,095 | 19.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 45 | $18,396 | $3,932 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 32 | 34 | $13,520 | $2,710 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 16 | 17 | $9,991 | $2,057 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 27 | 27 | $7,278 | $1,441 | 19.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2022 | 57 | 57 | $1,983 | $379.99 | 19.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 43 | 164 | $146,695 | $31,012 | 21.1% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 725 | 859 | $30,065 | $6,099 | 20.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 25 | $10,355 | $2,235 | 21.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 34 | 35 | $7,905 | $1,936 | 24.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 19 | 22 | $7,824 | $1,915 | 24.5% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Office | 2021 | 43 | 44 | $1,540 | $281.58 | 18.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 46 | 133 | $118,433 | $26,097 | 22.0% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 695 | 853 | $29,215 | $6,264 | 21.4% |
About Dr. David Morrow, MD
Dr. David Morrow, MD is a Cardiovascular Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1316928039.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Morrow, MD has received a total of $150,040 in payments from pharmaceutical and medical device companies, with $20,829 received in 2024. These payments were reported across 122 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($74,713).
As a Medicare-enrolled provider, Morrow has provided services to 3,777 Medicare beneficiaries, totaling 4,912 services with total Medicare billing of $187,692. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Boston, MA
- Active Since 11/09/2005
- Last Updated 05/01/2012
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1316928039
Products in Payments
- RDI Research (Device) $20,417
- ZONTIVITY (Drug) $19,792
- CD cobas Reagents (Device) $14,917
- XIENCE SIERRA (Device) $6,309
- ENTRESTO (Drug) $5,923
- OPTIS (Device) $2,250
- LEQVIO (Drug) $1,065
- MD cobas Instruments and Reagents (Device) $368.40
- Impella (Device) $220.60
- ARCHITECT (Device) $9.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Boston
Dr. Elizabeth Nabel, M.d, M.D
Cardiovascular Disease — Payments: $3.0M
Cardiovascular Disease $3.0M
Kenneth Rosenfield, M.d, M.D
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Eric Secemsky, Md, Msc, MD, MSC
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Benjamin Scirica, M.d, M.D
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Jorge Plutzky, Md, MD
Cardiovascular Disease — Payments: $973,823
Cardiovascular Disease $973,823
Christopher Cannon, Md, MD
Cardiovascular Disease — Payments: $869,405
Cardiovascular Disease $869,405